Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-26-003166
Filing Date
2026-03-11
Accepted
2026-03-11 16:30:55
Documents
53
Period of Report
2026-01-31

Document Format Files

Seq Description Document Type Size
1 z3626110q.htm   iXBRL 10-Q 831686
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7771
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7686
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 4858
  Complete submission text file 0001214659-26-003166.txt   3851704

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20260131.xsd EX-101.SCH 36947
6 XBRL CALCULATION FILE alzm-20260131_cal.xml EX-101.CAL 29791
7 XBRL DEFINITION FILE alzm-20260131_def.xml EX-101.DEF 144685
8 XBRL LABEL FILE alzm-20260131_lab.xml EX-101.LAB 251746
9 XBRL PRESENTATION FILE alzm-20260131_pre.xml EX-101.PRE 208253
55 EXTRACTED XBRL INSTANCE DOCUMENT z3626110q_htm.xml XML 508226
Mailing Address 480 PEACHTREE ROAD NE, SECOND FLOOR SUITE 103 ATLANTA GA 30326
Business Address 480 PEACHTREE ROAD NE, SECOND FLOOR SUITE 103 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

EIN.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 26743866
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)